Characteristics Associated with Pre-Exposure Prophylaxis Discussion and Use Among Transgender Women Without HIV Infection - National HIV Behavioral Surveillance Among Transgender Women, Seven Urban Areas, United States, 2019-2020

Elana Morris, CDC, Atlanta, GA
Anna Teplinskaya, CDC, Atlanta, GA
Evelyn Olansky, CDC, Atlanta, GA
Jeffrey Kemp Rinderle, CDC, Atlanta, GA
Johanna Chapin-Bardales, CDC, Atlanta, GA
National HIV Behavioral Surveillance Among Transgender Women Study Group:
Narquis Barak, CresentCare
Kathleen A. Brady, Philadelphia Department of Public Health
Sarah Braunstein, New York City Department of Health and Mental Hygiene
Jasmine Davis, CresentCare
Sara Glick, University of Washington, Seattle, WA
Andrea Harrington, Philadelphia Department of Public Health
Jasmine Lopez, New York City Department of Health and Mental Hygiene
Yingbo Ma, Los Angeles County Department of Public Health
Aleks Martin, Public Health - Seattle & King County
Genetha Mustaafaa, Georgia Department of Public Health
Tanner Nassau, Philadelphia Department of Public Health
Gia Olaes, Los Angeles County Department of Public Health
Jennifer Reuer, Washington State Department of Health
Alexis Rivera, New York City Department of Health and Mental Hygiene
William T. Robinson, LSU Health Sciences Center - New Orleans
et al

See article for full author list.

Abstract

CDC recommends pre-exposure prophylaxis (PrEP) for transgender women who have sex with men and who report sexual behaviors that place them at substantial ongoing risk for HIV exposure, including those who engage in nonsterile syringe sharing. Providing transgender women with access to PrEP is a critical strategy for reducing HIV acquisition and ending the HIV epidemic. Survey results from the National HIV Behavioral Surveillance Among Transgender Women were used to assess characteristics associated with past-year discussions of PrEP with a health care provider and PrEP use. Bivariate analyses were conducted to assess the association between covariates (sociodemographic, HIV-associated characteristics, and gender-affirming care) and each outcome, accounting for sampling design. All covariates that were statistically significant at p<0.05 in the bivariate analyses were included in multivariate models, and manual backward elimination was used to obtain final models that retained statistically significant covariates. Among 902 transgender women from seven urban areas in the United States without HIV infection in the analyses, 57% had recently discussed PrEP with a health care provider, and 32% recently had used PrEP. In the final multivariate model, the following subgroups of transgender women were more likely to report recent PrEP use: those who identified as Black or African American or Hispanic or Latina, had two or more sex partners in the past 12 months, had condomless sex in the past 12 months, reported their last sex partner was infected with HIV, had condomless sex with their last sex partner whose HIV status was positive or unknown, ever had transgender-specific health care, and currently had transgender-specific health insurance coverage. Participants who were less likely to have recently used PrEP were those who wanted to but were not currently taking hormones and those aged < 40 years. Providing increased access to gender-affirming care and training health care providers who serve transgender women to incorporate PrEP into existing services might increase PrEP use among transgender women.